Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Perphenazine enanthate

From Wikipedia, the free encyclopedia
Typical antipsychotic medication
Pharmaceutical compound
Perphenazine enanthate
Clinical data
Trade namesDecentan Depot, Peratsin Enantaatti, Trilafon, Trilafon Enantato, Trilafon Enantat, Trilifan Retard
Other namesPerphenazine enantate
Routes of
administration		Intramuscular injection
Drug classTypical antipsychotic
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl heptanoate
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard(EPA)
ECHA InfoCard100.037.739Edit this at Wikidata
Chemical and physical data
FormulaC28H38ClN3O2S
Molar mass516.14 g·mol−1
3D model (JSmol)
  • CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
  • InChI=1S/C28H38ClN3O2S/c1-2-3-4-5-11-28(33)34-21-20-31-18-16-30(17-19-31)14-8-15-32-24-9-6-7-10-26(24)35-27-13-12-23(29)22-25(27)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3
  • Key:PWEGQJCIAMJJHC-UHFFFAOYSA-N

Perphenazine enanthate, sold under the brand nameTrilafon Enantat among others, is atypical antipsychotic and adepotantipsychotic ester which is used in the treatment ofschizophrenia and has been marketed inEurope.[1][2][3][4][5][6] It is formulated insesame oil and administered byintramuscular injection and acts as a long-lastingprodrug ofperphenazine.[2][3][4][5][6] Perphenazine enanthate is used at a dose of 25 to 200 mg once every 2 weeks by injection, with atime to peak levels of 2 to 3 days and anelimination half-life of 4 to 7 days.[2][3][4][5][6]

Pharmacokinetics of long-acting injectable antipsychotics
MedicationBrand nameClassVehicleDosageTmaxt1/2 singlet1/2 multiplelogPcRef
Aripiprazole lauroxilAristadaAtypicalWatera441–1064 mg/4–8 weeks24–35 days?54–57 days7.9–10.0
Aripiprazole monohydrateAbilify MaintenaAtypicalWatera300–400 mg/4 weeks7 days?30–47 days4.9–5.2
Bromperidol decanoateImpromen DecanoasTypicalSesame oil40–300 mg/4 weeks3–9 days?21–25 days7.9[7]
Clopentixol decanoateSordinol DepotTypicalViscoleob50–600 mg/1–4 weeks4–7 days?19 days9.0[8]
Flupentixol decanoateDepixolTypicalViscoleob10–200 mg/2–4 weeks4–10 days8 days17 days7.2–9.2[8][9]
Fluphenazine decanoateProlixin DecanoateTypicalSesame oil12.5–100 mg/2–5 weeks1–2 days1–10 days14–100 days7.2–9.0[10][11][12]
Fluphenazine enanthateProlixin EnanthateTypicalSesame oil12.5–100 mg/1–4 weeks2–3 days4 days?6.4–7.4[11]
FluspirileneImap, RedeptinTypicalWatera2–12 mg/1 week1–8 days7 days?5.2–5.8[13]
Haloperidol decanoateHaldol DecanoateTypicalSesame oil20–400 mg/2–4 weeks3–9 days18–21 days7.2–7.9[14][15]
Olanzapine pamoateZyprexa RelprevvAtypicalWatera150–405 mg/2–4 weeks7 days?30 days–
Oxyprothepin decanoateMeclopinTypical?????8.5–8.7
Paliperidone palmitateInvega SustennaAtypicalWatera39–819 mg/4–12 weeks13–33 days25–139 days?8.1–10.1
Perphenazine decanoateTrilafon DekanoatTypicalSesame oil50–200 mg/2–4 weeks??27 days8.9
Perphenazine enanthateTrilafon EnanthateTypicalSesame oil25–200 mg/2 weeks2–3 days?4–7 days6.4–7.2[16]
Pipotiazine palmitatePiportil LongumTypicalViscoleob25–400 mg/4 weeks9–10 days?14–21 days8.5–11.6[9]
Pipotiazine undecylenatePiportil MediumTypicalSesame oil100–200 mg/2 weeks???8.4
RisperidoneRisperdal ConstaAtypicalMicrospheres12.5–75 mg/2 weeks21 days?3–6 days–
Zuclopentixol acetateClopixol AcuphaseTypicalViscoleob50–200 mg/1–3 days1–2 days1–2 days4.7–4.9
Zuclopentixol decanoateClopixol DepotTypicalViscoleob50–800 mg/2–4 weeks4–9 days?11–21 days7.5–9.0
Note: All byintramuscular injection.Footnotes:a =Microcrystalline ornanocrystallineaqueous suspension.b = Low-viscosityvegetable oil (specificallyfractionated coconut oil withmedium-chain triglycerides).c = Predicted, fromPubChem andDrugBank.Sources:Main: See template.

See also

[edit]

References

[edit]
  1. ^Swiss Pharmaceutical Society (2000). Swiss Pharmaceutical Society (ed.).Index Nominum 2000: International Drug Directory. Taylor & Francis. pp. 811–.ISBN 978-3-88763-075-1.
  2. ^abcAltamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E (2003). "Intramuscular preparations of antipsychotics: uses and relevance in clinical practice".Drugs.63 (5):493–512.doi:10.2165/00003495-200363050-00004.PMID 12600227.S2CID 46973260.
  3. ^abcDavis JM, Matalon L, Watanabe MD, Blake L, Metalon L (May 1994). "Depot antipsychotic drugs. Place in therapy".Drugs.47 (5):741–73.doi:10.2165/00003495-199447050-00004.PMID 7520856.S2CID 46962898.
  4. ^abcTaylor D (November 2009)."Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review".Br J Psychiatry Suppl.52: S13–9.doi:10.1192/bjp.195.52.s13.PMID 19880912.S2CID 1692443.
  5. ^abcSpanarello S, La Ferla T (2014). "The pharmacokinetics of long-acting antipsychotic medications".Curr Clin Pharmacol.9 (3):310–7.doi:10.2174/15748847113089990051.PMID 23343447.
  6. ^abcDe Risio A, Lang AP (February 2014). "History and therapeutic rationale of long acting antipsychotics".Curr Clin Pharmacol.9 (1):39–52.doi:10.2174/15748847113089990057.PMID 23343446.
  7. ^Parent M, Toussaint C, Gilson H (1983). "Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation".Current Therapeutic Research.34 (1):1–6.
  8. ^abJørgensen A, Overø KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels".Acta Psychiatrica Scandinavica. Supplementum.279:41–54.doi:10.1111/j.1600-0447.1980.tb07082.x.PMID 6931472.
  9. ^abReynolds JE (1993). "Anxiolytic sedatives, hypnotics and neuroleptics.".Martindale: The Extra Pharmacopoeia (30th ed.). London: Pharmaceutical Press. pp. 364–623.
  10. ^Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (May 1984). "Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches".The Journal of Clinical Psychiatry.45 (5 Pt 2):50–9.PMID 6143748.
  11. ^abCurry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979)."Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man".British Journal of Clinical Pharmacology.7 (4):325–31.doi:10.1111/j.1365-2125.1979.tb00941.x.PMC 1429660.PMID 444352.
  12. ^Young D, Ereshefsky L, Saklad SR, Jann MW, Garcia N (1984).Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.). 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. Dallas, Texas.
  13. ^Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, Hérin VV, Schaper WK (November 1970). "The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug".Arzneimittel-Forschung.20 (11):1689–98.PMID 4992598.
  14. ^Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis".Drugs.33 (1):31–49.doi:10.2165/00003495-198733010-00002.PMID 3545764.
  15. ^Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up".International Pharmacopsychiatry.17 (4):238–46.doi:10.1159/000468580.PMID 7185768.
  16. ^Larsson M, Axelsson R, Forsman A (1984). "On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate".Current Therapeutic Research.36 (6):1071–88.


Typical
Disputed
Atypical
Others
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
H1
Agonists
Antagonists
H2
Agonists
Antagonists
H3
Agonists
Antagonists
H4
Agonists
Antagonists
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT3–7
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
σ1
σ2
Unsorted
Classes
Antidepressants
(Tricyclic antidepressants(TCAs))
Antihistamines
Antipsychotics
Anticonvulsants
Anticholinergics
Others


Stub icon

Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Perphenazine_enanthate&oldid=1283173829"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp